The Age
·general
·1 hour ago
NeuroScientific hails 80% clinical response in Crohn’s stem cell program
NeuroScientific Biopharmaceuticals reported an 80% clinical response rate in its StemSmart stem cell therapy for fistulising Crohn's disease, with four of five patients showing improvement under its Special Access Program. All five patients demonstrated healing improvements, with no serious adverse events recorded. The results support the company's move toward phase 2 trials in Australia later.
Summary by Glance · The Age
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI